Calithera Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer. It offers programs such as Pipeline, Glutaminase Inhibitor, and Arginase Inhibitor. The company was founded by James A. Wells and Susan M. Molineaux on March 9, 2010 and is headquartered in South San Francisco, CA.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CALA
CUSIPN/A
Phone650-870-1000
Debt
Debt-to-Equity RatioN/A
Current Ratio13.67
Quick Ratio13.67
Price-To-Earnings
Trailing P/E Ratio-5.36
Forward P/E Ratio-3.54
P/E GrowthN/A
Sales & Book Value
Annual Sales$25.95 million
Price / Sales6.24
Cash FlowN/A
Price / CashN/A
Book Value$4.24 per share
Price / Book1.06
Profitability
EPS (Most Recent Fiscal Year)($0.84)
Net Income$-27,820,000.00
Net Margins-90.65%
Return on Equity-22.09%
Return on Assets-18.12%
Miscellaneous
Employees73
Outstanding Shares35,990,000
Market Cap$160.14 million
Calithera Biosciences (NASDAQ:CALA) Frequently Asked Questions
What is Calithera Biosciences' stock symbol?
Calithera Biosciences trades on the NASDAQ under the ticker symbol "CALA."
How were Calithera Biosciences' earnings last quarter?
Calithera Biosciences Inc (NASDAQ:CALA) released its quarterly earnings data on Tuesday, August, 7th. The biotechnology company reported ($0.09) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.32) by $0.23. The biotechnology company earned $17.07 million during the quarter, compared to analyst estimates of $5.17 million. Calithera Biosciences had a negative net margin of 90.65% and a negative return on equity of 22.09%. View Calithera Biosciences' Earnings History.
When is Calithera Biosciences' next earnings date?
What price target have analysts set for CALA?
3 Wall Street analysts have issued 1 year price targets for Calithera Biosciences' shares. Their predictions range from $14.00 to $14.00. On average, they expect Calithera Biosciences' share price to reach $14.00 in the next twelve months. This suggests a possible upside of 211.1% from the stock's current price. View Analyst Price Targets for Calithera Biosciences.
What is the consensus analysts' recommendation for Calithera Biosciences?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Calithera Biosciences in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Calithera Biosciences.
Who are some of Calithera Biosciences' key competitors?
Some companies that are related to Calithera Biosciences include Viking Therapeutics (VKTX), Adamas Pharmaceuticals (ADMS), GlycoMimetics (GLYC), AC Immune (ACIU), Progenics Pharmaceuticals (PGNX), Dova Pharmaceuticals (DOVA), Eidos Therapeutics (EIDX), Verastem (VSTM), Collegium Pharmaceutical (COLL), Prothena (PRTA), ArQule (ARQL), ChemoCentryx (CCXI), Homology Medicines (FIXX), Insys Therapeutics (INSY) and Evolus (EOLS).
Who are Calithera Biosciences' key executives?
Calithera Biosciences' management team includes the folowing people:
- Susan M. Molineaux, President, Chief Executive Officer & Director
- Stephanie Wong, Secretary & Senior Vice President-Finance
- Sumita Ray, Chief Compliance Officer, SVP & General Counsel
- Hagit Glickman, Vice President, Head-People & Culture
- Jennifer Isacoff McNealey, Vice President, Investor Relations and Strategy
Has Calithera Biosciences been receiving favorable news coverage?
Press coverage about CALA stock has been trending somewhat positive this week, Accern Sentiment reports. The research firm identifies negative and positive media coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Calithera Biosciences earned a daily sentiment score of 0.10 on Accern's scale. They also assigned media headlines about the biotechnology company an impact score of 47.77 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future. View Recent Headlines for Calithera Biosciences.
Who are Calithera Biosciences' major shareholders?
Calithera Biosciences' stock is owned by a number of of retail and institutional investors. Top institutional investors include BlackRock Inc. (9.33%), Federated Investors Inc. PA (5.27%), Dimensional Fund Advisors LP (2.21%), American Century Companies Inc. (1.54%), Alambic Investment Management L.P. (0.73%) and Bank of New York Mellon Corp (0.45%). Company insiders that own Calithera Biosciences stock include Adage Capital Partners Gp, LL, Curtis Hecht and Keith Orford. View Institutional Ownership Trends for Calithera Biosciences.
Which major investors are selling Calithera Biosciences stock?
CALA stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, American Century Companies Inc., Renaissance Technologies LLC, Schwab Charles Investment Management Inc. and Acadian Asset Management LLC. View Insider Buying and Selling for Calithera Biosciences.
Which major investors are buying Calithera Biosciences stock?
CALA stock was purchased by a variety of institutional investors in the last quarter, including Federated Investors Inc. PA, Dimensional Fund Advisors LP, Alambic Investment Management L.P., BlackRock Inc., Hikari Power Ltd and Bank of New York Mellon Corp. View Insider Buying and Selling for Calithera Biosciences.
How do I buy shares of Calithera Biosciences?
Shares of CALA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Calithera Biosciences' stock price today?
One share of CALA stock can currently be purchased for approximately $4.50.
How big of a company is Calithera Biosciences?
Calithera Biosciences has a market capitalization of $160.14 million and generates $25.95 million in revenue each year. The biotechnology company earns $-27,820,000.00 in net income (profit) each year or ($0.84) on an earnings per share basis. Calithera Biosciences employs 73 workers across the globe.
How can I contact Calithera Biosciences?
Calithera Biosciences' mailing address is 343 OYSTER POINT BLVD. SUITE 200, SOUTH SAN FRANCISCO CA, 94080. The biotechnology company can be reached via phone at 650-870-1000 or via email at [email protected]
MarketBeat Community Rating for Calithera Biosciences (NASDAQ CALA)
MarketBeat's community ratings are surveys of what our community members think about Calithera Biosciences and other stocks. Vote "Outperform" if you believe CALA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CALA will underperform the S&P 500 over the long term. You may vote once every thirty days.
